Collaborative Arrangements and Licensing Agreements - AstraZeneca (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025 USD ($) Agreement	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($) Agreement	Jun. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)
AstraZeneca [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Number of collaboration agreements (in Agreement) | Agreement	2		2
Cumulative payments received	$ 905,000		$ 905,000
Revenue	54,288	$ 15,960	74,577	$ 27,645
Deferred revenue	$ 0		$ 0		$ 0
WAINUA [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Number of collaboration agreements (in Agreement) | Agreement	1		1
Cardiovascular, Renal and Metabolic Diseases [Member]
Collaborative Arrangements and Licensing Agreements [Abstract]
Number of collaboration agreements (in Agreement) | Agreement	1		1
Revenue	$ 30,000
Next payment to be achieved	$ 20,000		$ 20,000